Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
28
04
2021
revised:
12
09
2021
accepted:
16
09
2021
entrez:
2
12
2021
pubmed:
3
12
2021
medline:
15
3
2022
Statut:
ppublish
Résumé
As countries move towards the UNAIDS's 95-95-95 targets and with strong evidence that undetectable equals untransmittable, it is increasingly important to assess whether those with HIV who are receiving antiretroviral therapy (ART) achieve viral suppression. We estimated the proportions of children and adolescents and adults with viral suppression at 1, 2, and 3 years after initiating ART. In this retrospective cohort study, seven regional cohorts from the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium contributed data from individuals initiating ART between Jan 1, 2010, and Dec 31, 2019, at 148 sites in 31 countries with annual viral load monitoring. Only people with HIV who started ART after the time a site started routine viral load monitoring were included. Data up to March 31, 2020, were analysed. We estimated the proportions of children and adolescents (aged <18 years at ART initiation) and adults (aged ≥18 years at ART initiation) with viral suppression (viral load <1000 copies per mL) at 1, 2, and 3 years after ART initiation using an intention-to-treat approach and an adjusted approach that accounted for missing viral load measurements. 21 594 children and adolescents (11 812 [55%] female, 9782 [45%] male) from 106 sites in 22 countries and 255 662 adults (163 831 [64%] female, 91 831 [36%] male) from 143 sites in 30 countries were included. Using the intention-to-treat approach, the proportion of children and adolescents with viral suppression was 7303 (36%) of 20 478 at 1 year, 5709 (30%) of 19 135 at 2 years, and 4287 (24%) of 17 589 at 3 years after ART initiation; the proportion of adults with viral suppression was 106 541 (44%) of 240 600 at 1 year, 79 141 (36%) of 220 925 at 2 years, and 57 970 (29%) of 201 124 at 3 years after ART initiation. After adjusting for missing viral load measurements among those who transferred, were lost to follow-up, or who were in follow-up without viral load testing, the proportion of children and adolescents with viral suppression was 12 048 (64% [plausible range 43-81]) of 18 835 at 1 year, 10 796 (62% [41-77]) of 17 553 at 2 years, and 9177 (59% [38-91]) of 15 667 at 3 years after ART initiation; the proportion of adults with viral suppression was 176 964 (79% [53-80]) of 225 418 at 1 year, 145 552 (72% [48-79]) of 201 238 at 2 years, and 115 260 (65% [43-69]) of 178 458 at 3 years after ART initiation. Although adults with HIV are approaching the global target of 95% viral suppression, progress among children and adolescents is much slower. Substantial efforts are still needed to reach the viral suppression target for children and adolescents. US National Institutes of Health.
Sections du résumé
BACKGROUND
As countries move towards the UNAIDS's 95-95-95 targets and with strong evidence that undetectable equals untransmittable, it is increasingly important to assess whether those with HIV who are receiving antiretroviral therapy (ART) achieve viral suppression. We estimated the proportions of children and adolescents and adults with viral suppression at 1, 2, and 3 years after initiating ART.
METHODS
In this retrospective cohort study, seven regional cohorts from the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium contributed data from individuals initiating ART between Jan 1, 2010, and Dec 31, 2019, at 148 sites in 31 countries with annual viral load monitoring. Only people with HIV who started ART after the time a site started routine viral load monitoring were included. Data up to March 31, 2020, were analysed. We estimated the proportions of children and adolescents (aged <18 years at ART initiation) and adults (aged ≥18 years at ART initiation) with viral suppression (viral load <1000 copies per mL) at 1, 2, and 3 years after ART initiation using an intention-to-treat approach and an adjusted approach that accounted for missing viral load measurements.
FINDINGS
21 594 children and adolescents (11 812 [55%] female, 9782 [45%] male) from 106 sites in 22 countries and 255 662 adults (163 831 [64%] female, 91 831 [36%] male) from 143 sites in 30 countries were included. Using the intention-to-treat approach, the proportion of children and adolescents with viral suppression was 7303 (36%) of 20 478 at 1 year, 5709 (30%) of 19 135 at 2 years, and 4287 (24%) of 17 589 at 3 years after ART initiation; the proportion of adults with viral suppression was 106 541 (44%) of 240 600 at 1 year, 79 141 (36%) of 220 925 at 2 years, and 57 970 (29%) of 201 124 at 3 years after ART initiation. After adjusting for missing viral load measurements among those who transferred, were lost to follow-up, or who were in follow-up without viral load testing, the proportion of children and adolescents with viral suppression was 12 048 (64% [plausible range 43-81]) of 18 835 at 1 year, 10 796 (62% [41-77]) of 17 553 at 2 years, and 9177 (59% [38-91]) of 15 667 at 3 years after ART initiation; the proportion of adults with viral suppression was 176 964 (79% [53-80]) of 225 418 at 1 year, 145 552 (72% [48-79]) of 201 238 at 2 years, and 115 260 (65% [43-69]) of 178 458 at 3 years after ART initiation.
INTERPRETATION
Although adults with HIV are approaching the global target of 95% viral suppression, progress among children and adolescents is much slower. Substantial efforts are still needed to reach the viral suppression target for children and adolescents.
FUNDING
US National Institutes of Health.
Identifiants
pubmed: 34856180
pii: S2352-3018(21)00265-4
doi: 10.1016/S2352-3018(21)00265-4
pmc: PMC8782625
mid: NIHMS1769075
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e766-e775Subventions
Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI038855
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI037613
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020790
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA016893
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035042
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036297
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062246
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069434
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI037984
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103397
Pays : United States
Organisme : NIAAA NIH HHS
ID : P01 AA029545
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA011602
Pays : United States
Organisme : NEI NIH HHS
ID : K23 EY013707
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA165937
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI031834
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM133807
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035004
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069432
Pays : United States
Organisme : NIMHD NIH HHS
ID : G12 MD007583
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA000432
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146205
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036935
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007587
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA004334
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI124872
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034989
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035041
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI067039
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI035043
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069432
Pays : United States
Organisme : NCI NIH HHS
ID : N02CP55504
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI038858
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008057
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068636
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034994
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000052
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG059505
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000454
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008052
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI110527
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI093197
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069918
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI065298
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103401
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA013566
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000083
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA012568
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146202
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035040
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103390
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034993
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI103408
Pays : United States
Organisme : NIDA NIH HHS
ID : F31 DA037788
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035039
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008067
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036219
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 CP010176
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020794
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD032632
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI042590
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003098
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests AHS reports grant support to her institution for activities unrelated to this work. MGL reports unrestricted grants from Gilead Sciences, Janssen–Cilag, and ViiV Healthcare. CPC reports grant support from National Institutes of Health (NIH; U01AI069923) and consultation fees and honoraria from GSK–ViiV, and Merck. KNA reports grant support from NIH, with funding payments made to her institution; and consultation fees from the All of Us Research Program (NIH) and Trio Health. All other authors report no competing interests.
Références
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e67-75
pubmed: 24977471
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171190
Bull World Health Organ. 2013 May 1;91(5):377-385E
pubmed: 23678201
J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11
pubmed: 19745753
Lancet HIV. 2015 Jul;2(7):e271-8
pubmed: 26423252
PLoS Med. 2019 May 31;16(5):e1002811
pubmed: 31150380
Clin Infect Dis. 2016 Apr 1;62(7):935-944
pubmed: 26679625
PLoS One. 2018 Jan 11;13(1):e0190659
pubmed: 29324811
AIDS Res Hum Retroviruses. 2009 Aug;25(8):757-63
pubmed: 19618996
J Int AIDS Soc. 2018 Dec;21(12):e25215
pubmed: 30548817
AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S81-S88
pubmed: 33560041
S Afr Med J. 2019 Feb 26;109(3):174-177
pubmed: 30834874
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):319-329
pubmed: 28708808
Clin Infect Dis. 2016 Dec 15;63(12):1645-1654
pubmed: 27660236
JAMA. 2008 Aug 6;300(5):506-7
pubmed: 18677022
Trop Med Int Health. 2016 Mar;21(3):325-33
pubmed: 26681359
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e46-55
pubmed: 25692336
Lancet HIV. 2015 Mar;2(3):e107-16
pubmed: 26424542
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21668
pubmed: 28530037
PLoS Med. 2014 Sep 09;11(9):e1001718
pubmed: 25203931
AIDS. 2006 Oct 24;20(16):2051-64
pubmed: 17053351